Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Edgewise Therapeutics Inc EWTX

Healthcare
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. It has built its muscle-focused drug discovery platform. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small... see more

Recent & Breaking News (NDAQ:EWTX)

Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)

Business Wire January 5, 2022

Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study

Business Wire December 15, 2021

Edgewise Therapeutics to Participate at Evercore ISI 4th Annual HEALTHCONx Conference on December 2

Business Wire November 17, 2021

Edgewise Therapeutics Reports Third Quarter 2021 Financial Results

Business Wire November 10, 2021

Edgewise Therapeutics Announces Positive Topline Results from the EDG-5506 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HVs) and Doses First Becker Muscular Dystrophy (BMD) Patients

Business Wire October 28, 2021

Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event on September 23

Business Wire September 14, 2021

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Individuals with Becker Muscular Dystrophy (BMD)

Business Wire August 16, 2021

Edgewise Therapeutics Reports Second Quarter 2021 Financial Results

Business Wire August 9, 2021

Edgewise Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 11

Business Wire August 4, 2021

Edgewise Therapeutics to Present at the PPMD Annual Conference and the New Directions in Biology and Disease of Skeletal Muscle Conference

Business Wire June 22, 2021

Edgewise Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

Business Wire June 1, 2021

 Edgewise Therapeutics Reports First Quarter 2021 Financial Results and Recent Highlights

Business Wire May 13, 2021

Edgewise Therapeutics Announces Publication of Data Demonstrating the Elevation of Fast but Not Slow Skeletal Muscle Fiber Injury Biomarkers in the Circulation of Patients with Becker and Duchenne Muscular Dystrophy

Business Wire May 4, 2021

Edgewise Therapeutics Appoints Joanne Donovan, M.D., Ph.D., as Chief Medical Officer

Business Wire April 27, 2021

Edgewise Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Business Wire March 30, 2021

Edgewise Therapeutics Announces Pricing of Initial Public Offering

Business Wire March 25, 2021